Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.